Led · Seed · Sep 2025

Adaptyv Biosystems operates an automated, cloud-accessible laboratory that closes the critical “design-test-learn” loop for AI-driven protein engineering. Its platform performs high-throughput experimental assays to verify the function of proteins proposed by computational models, addressing the cost and accessibility barriers that typically slow validation. In beta, the system has already tested more than 10,000 proteins in partnership with about 30 pharmaceutical and biotech teams, and in one international competition it boosted hit rates from 2.5 % to 13 % within two months. By automating wet-lab steps and streaming data back to model builders, the company aims to accelerate the creation of therapeutic and industrial proteins. With fresh capital, Adaptyv plans to broaden the menu of assays, deepen robotic automation, and launch an API that pipes experimental results directly into AI models. The company is headquartered in the Lausanne area (Épalinges) and positions itself as an infrastructure provider for the growing protein-design ecosystem.

Participated · Seed · Mar 2025

Founded in 2024, Loopia provides a platform that centralizes conversations from channels like WhatsApp and marketplaces including Mercado Livre, TikTok Shop, Amazon and Shopee. Its AI agents can respond automatically, prioritize demands, generate insights and execute tasks across the customer journey. The platform connects customer service, marketing and operations within a single environment to streamline seller workflows. Loopia plans to accelerate product development and expand the number of integrated channels following its recent funding. The company raised a R$6.5 million seed round with an additional R$2 million commitment tied to growth, backing its commercial expansion plans. Management projects fivefold growth over the next 18 months supported by the new capital.

Participated · Series C · Jan 2024

Ajira develops behavior-recognition AI and commercializes it as the AI security product 'AI Security asilla'. Headquartered in Machida, Tokyo, the company has been selling asilla for about a year with deployments in large commercial and complex facilities, hospitals, educational institutions, railways, airports and other public and private infrastructure. Asilla operates on existing cameras, can process up to 50 camera feeds per server in its enterprise plan, and uses a patented "anomaly detection" approach to identify precursors to incidents. The product provides local, secure 24/7 monitoring and instant notifications (within one second) when abnormal behavior is detected. Planned feature updates include fire/flame detection and unattended-object detection to broaden use cases in facility and transportation security. Financially, Ajira has completed a Series C extension bringing the round to ¥760M to date and has raised ¥1.7B in total funding. Asilla has developed proprietary behavior-recognition AI and sells an AI security system called AI Security asilla that analyzes existing camera feeds to detect abnormal or suspicious behavior. The product can run locally, process up to 50 cameras per server, and uses a patented “discomfort detection” method for early warning; it is deployed in complex facilities, commercial sites, hospitals, educational institutions and transportation infrastructure across Japan. The company emphasizes low initial cost by leveraging existing cameras and a secure, local network architecture to avoid external video leakage. Asilla is expanding its product lineup and sales network to grow revenue by entering markets beyond its traditional customers. Management plans to strengthen the asilla sales organization, continue evolving the core AI technology, and enhance corporate governance to build a scalable business foundation. The company is headquartered in Machida, Tokyo, and is led by CEO Daisuke Kimura. Asilla develops proprietary behavioral-recognition AI for video analytics and has released a facility-targeted AI security system called “Asilla.” The company reports growing deployments in large commercial facilities and office buildings since the product launch this year. It positions the system to address security industry labor shortages and improve safety, and it says it intends to pursue global expansion in the future. Asilla plans to use new capital and partnerships to strengthen its sales channels, advance its behavior-recognition models, and enhance corporate governance. The company was founded on June 1, 2015, and is headquartered in Machida, Tokyo. Reported corporate details include paid-in capital of ¥56,125 thousand.

Participated · Series B · Mar 2022

Kither Biotech develops novel therapies for rare pulmonary diseases with a specific focus on cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). Its lead candidate, KIT2014, is a cell-permeable peptide designed to modulate intracellular cAMP levels and is being developed as an inhaled add-on therapy to improve outcomes for CF patients. The company plans to complete preclinical studies for KIT2014 in 2022 and to initiate a Phase 1/2A clinical trial thereafter. Kither is also launching preclinical development of KITCL27, a PI3K inhibitor pro-drug being developed as a monotherapy for IPF. The company is a spin-off from the University of Turin and collaborates with the Molecular Biotechnology Center and other research centres. Leadership includes CEO Dr. Vincent Metzler, CFO Marco Kevin Malisani (formerly CEO), and a board chaired by Laura Iris Ferro. Kither Biotech is a Turin-based biopharma spin-off from the University of Turin focused on identifying and developing drug candidates for pulmonary diseases, including cystic fibrosis, asthma, COPD and idiopathic pulmonary fibrosis. Its lead candidate, KIT-2014, is protected by a family of international patents and has received Orphan Drug designation from the European Medicines Agency. Preclinical results for KIT-2014 have been replicated in top centres active in cystic fibrosis research, including the University of Carolina at Chapel Hill. The company will use the new funds to complete preclinical studies and initiate a phase I/II clinical trial of KIT-2014 in healthy volunteers and patients during 2020. It also plans to advance a second development program testing another candidate for idiopathic pulmonary fibrosis and other respiratory diseases. Kither actively collaborates with the Molecular Biotechnology Center (University of Turin) and other research centres worldwide.